JP2017518043A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017518043A5 JP2017518043A5 JP2016564998A JP2016564998A JP2017518043A5 JP 2017518043 A5 JP2017518043 A5 JP 2017518043A5 JP 2016564998 A JP2016564998 A JP 2016564998A JP 2016564998 A JP2016564998 A JP 2016564998A JP 2017518043 A5 JP2017518043 A5 JP 2017518043A5
- Authority
- JP
- Japan
- Prior art keywords
- complex
- polynucleotide
- antisense strand
- seq
- gene
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108091033319 polynucleotide Proteins 0.000 claims description 24
- 239000002157 polynucleotide Substances 0.000 claims description 24
- 102000040430 polynucleotide Human genes 0.000 claims description 24
- 230000000692 anti-sense effect Effects 0.000 claims description 14
- 239000008194 pharmaceutical composition Substances 0.000 claims description 10
- 229920001184 polypeptide Polymers 0.000 claims description 10
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 10
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 10
- 235000001014 amino acid Nutrition 0.000 claims description 8
- 150000001413 amino acids Chemical class 0.000 claims description 8
- 210000003169 central nervous system Anatomy 0.000 claims description 8
- 230000000295 complement effect Effects 0.000 claims description 8
- 108020004999 messenger RNA Proteins 0.000 claims description 8
- 101150081618 nox gene Proteins 0.000 claims description 8
- 239000002773 nucleotide Substances 0.000 claims description 8
- 125000003729 nucleotide group Chemical group 0.000 claims description 8
- 108090000623 proteins and genes Proteins 0.000 claims description 7
- 108010082699 NADPH Oxidase 4 Proteins 0.000 claims description 6
- 102100021872 NADPH oxidase 4 Human genes 0.000 claims description 6
- 201000010099 disease Diseases 0.000 claims description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 6
- 238000001990 intravenous administration Methods 0.000 claims description 6
- 238000000034 method Methods 0.000 claims description 5
- 102100025621 Cytochrome b-245 heavy chain Human genes 0.000 claims description 4
- 102000004019 NADPH Oxidase 1 Human genes 0.000 claims description 4
- 108090000424 NADPH Oxidase 1 Proteins 0.000 claims description 4
- 108010082739 NADPH Oxidase 2 Proteins 0.000 claims description 4
- 108091081021 Sense strand Proteins 0.000 claims description 4
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 4
- 238000001802 infusion Methods 0.000 claims description 3
- 238000010254 subcutaneous injection Methods 0.000 claims description 3
- 239000007929 subcutaneous injection Substances 0.000 claims description 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 2
- 108091034117 Oligonucleotide Proteins 0.000 claims description 2
- 208000006011 Stroke Diseases 0.000 claims description 2
- 238000007792 addition Methods 0.000 claims description 2
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 claims description 2
- 238000012217 deletion Methods 0.000 claims description 2
- 230000037430 deletion Effects 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 208000014674 injury Diseases 0.000 claims description 2
- 238000003780 insertion Methods 0.000 claims description 2
- 230000037431 insertion Effects 0.000 claims description 2
- 208000028867 ischemia Diseases 0.000 claims description 2
- 208000004296 neuralgia Diseases 0.000 claims description 2
- 230000004770 neurodegeneration Effects 0.000 claims description 2
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 2
- 208000021722 neuropathic pain Diseases 0.000 claims description 2
- 208000020016 psychiatric disease Diseases 0.000 claims description 2
- 230000001698 pyrogenic effect Effects 0.000 claims description 2
- 238000006467 substitution reaction Methods 0.000 claims description 2
- 230000008733 trauma Effects 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims 3
- 239000002131 composite material Substances 0.000 claims 2
- 210000004899 c-terminal region Anatomy 0.000 claims 1
- 108091033409 CRISPR Proteins 0.000 description 1
- 238000010354 CRISPR gene editing Methods 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461987228P | 2014-05-01 | 2014-05-01 | |
| US61/987,228 | 2014-05-01 | ||
| US201462033903P | 2014-08-06 | 2014-08-06 | |
| US62/033,903 | 2014-08-06 | ||
| US201562144598P | 2015-04-08 | 2015-04-08 | |
| US62/144,598 | 2015-04-08 | ||
| PCT/US2015/028743 WO2015168521A2 (en) | 2014-05-01 | 2015-05-01 | P97-polynucleotide conjugates |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017518043A JP2017518043A (ja) | 2017-07-06 |
| JP2017518043A5 true JP2017518043A5 (cg-RX-API-DMAC7.html) | 2018-06-14 |
| JP6847664B2 JP6847664B2 (ja) | 2021-03-24 |
Family
ID=53055138
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016564998A Expired - Fee Related JP6847664B2 (ja) | 2014-05-01 | 2015-05-01 | Ｐ９７−ポリヌクレオチド複合体 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US10058619B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3137610B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP6847664B2 (cg-RX-API-DMAC7.html) |
| CN (1) | CN106413757B (cg-RX-API-DMAC7.html) |
| AU (1) | AU2015252906C1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2943890A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2015168521A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2003222568B2 (en) | 2002-01-11 | 2009-05-07 | Bioasis Technologies, Inc. | Use of P97 as an enzyme delivery system for the delivery of therapeutic lysosomal enzymes |
| BR112014002219A2 (pt) | 2011-07-05 | 2018-08-07 | Bioasis Technologies Inc | conjugados anticorpo p97 e métodos de sua utilização |
| WO2014022515A1 (en) | 2012-07-31 | 2014-02-06 | Bioasis Technologies, Inc. | Dephosphorylated lysosomal storage disease proteins and methods of use thereof |
| ES2774549T3 (es) | 2013-03-13 | 2020-07-21 | Bioasis Technologies Inc | Fragmentos de P97 y usos de los mismos |
| WO2015117121A1 (en) * | 2014-02-03 | 2015-08-06 | Bioasis Technologies, Inc. | P97 fusion proteins |
| JP6605482B2 (ja) | 2014-02-19 | 2019-11-13 | バイオアシス テクノロジーズ インコーポレイテッド | Ｐ９７−ｉｄｓ融合タンパク質 |
| US20200277584A1 (en) | 2017-10-02 | 2020-09-03 | Denali Therapeutics Inc. | Fusion proteins comprising enzyme replacement therapy enzymes |
| KR20210024492A (ko) * | 2018-05-27 | 2021-03-05 | 바이오아시스 테크놀로지스 인크. | 고쉐병의 치료 |
| WO2020033331A1 (en) * | 2018-08-06 | 2020-02-13 | Martner Anna | Method and compositions for treating colon cancer and breast cancer |
| US20210355468A1 (en) * | 2020-05-18 | 2021-11-18 | Bioasis Technologies, Inc. | Compositions and methods for treating lewy body dementia |
| US20210393787A1 (en) * | 2020-06-17 | 2021-12-23 | Bioasis Technologies, Inc. | Compositions and methods for treating frontotemporal dementia |
| WO2023185946A1 (zh) * | 2022-03-30 | 2023-10-05 | 苏州瑞博生物技术股份有限公司 | 一种寡核苷酸缀合物、含有该寡核苷酸缀合物的组合物及制备方法和用途 |
| CN114948802A (zh) * | 2022-04-12 | 2022-08-30 | 露乐健康科技股份有限公司 | 一种改善睡眠不足人群皮肤不良状态的护肤组合物及其制备方法及护肤品 |
Family Cites Families (74)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4704362A (en) | 1977-11-08 | 1987-11-03 | Genentech, Inc. | Recombinant cloning vehicle microbial polypeptide expression |
| US4394448A (en) | 1978-02-24 | 1983-07-19 | Szoka Jr Francis C | Method of inserting DNA into living cells |
| US4391904A (en) | 1979-12-26 | 1983-07-05 | Syva Company | Test strip kits in immunoassays and compositions therein |
| US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4766075A (en) | 1982-07-14 | 1988-08-23 | Genentech, Inc. | Human tissue plasminogen activator |
| US5186941A (en) | 1983-05-06 | 1993-02-16 | Vestar, Inc. | Vesicle formulation for the controlled release of therapeutic agents |
| US4801542A (en) | 1984-10-12 | 1989-01-31 | Zymogenetics, Inc. | Expression of biologically active PDGF analogs in eucaryotic cells |
| US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
| GR860984B (en) | 1985-04-17 | 1986-08-18 | Zymogenetics Inc | Expression of factor vii and ix activities in mammalian cells |
| US4935349A (en) | 1986-01-17 | 1990-06-19 | Zymogenetics, Inc. | Expression of higher eucaryotic genes in aspergillus |
| US4800159A (en) | 1986-02-07 | 1989-01-24 | Cetus Corporation | Process for amplifying, detecting, and/or cloning nucleic acid sequences |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| US5091513A (en) | 1987-05-21 | 1992-02-25 | Creative Biomolecules, Inc. | Biosynthetic antibody binding sites |
| US5132405A (en) | 1987-05-21 | 1992-07-21 | Creative Biomolecules, Inc. | Biosynthetic antibody binding sites |
| US4866042A (en) | 1987-11-18 | 1989-09-12 | Neuwelt Edward A | Method for the delivery of genetic material across the blood brain barrier |
| US5720937A (en) | 1988-01-12 | 1998-02-24 | Genentech, Inc. | In vivo tumor detection assay |
| JP3040121B2 (ja) | 1988-01-12 | 2000-05-08 | ジェネンテク，インコーポレイテッド | 増殖因子レセプターの機能を阻害することにより腫瘍細胞を処置する方法 |
| US5672683A (en) | 1989-09-07 | 1997-09-30 | Alkermes, Inc. | Transferrin neuropharmaceutical agent fusion protein |
| US5932211A (en) | 1991-11-12 | 1999-08-03 | Women's And Children's Hospital | Glycosylation variants of iduronate 2-sulfatase |
| US5981194A (en) | 1992-07-10 | 1999-11-09 | University Of British Columbia | Use of p97 and iron binding proteins as diagnostic and therapeutic agents |
| US20020119095A1 (en) | 1992-07-10 | 2002-08-29 | Reinhard Gabathuler | Chemotherapeutic agents conjugated to p97 and their methods of use in treating neurological tumours |
| US6765087B1 (en) | 1992-08-21 | 2004-07-20 | Vrije Universiteit Brussel | Immunoglobulins devoid of light chains |
| ATE204325T1 (de) | 1993-04-29 | 2001-09-15 | Unilever Nv | Herstellung von antikörpern oder funktionstüchtig gemachten teilen davon, abgeleitet von schweren ketten von immunglobulinen von camelidae |
| AU2071695A (en) | 1994-03-17 | 1995-10-03 | Merck Patent Gmbh | Anti-EGFR single-chain FVS and anti-EGFR antibodies |
| TW492882B (en) | 1997-11-28 | 2002-07-01 | Caleb Pharmaceuticals Inc | Cholinergic antagonist plaster composition |
| US7214658B2 (en) | 2004-07-06 | 2007-05-08 | Tact Ip, Llc | Method of delivering a TNF antagonist to the brain of a human by perispinal administration without direct intrathecal injection |
| US6419944B2 (en) | 1999-02-24 | 2002-07-16 | Edward L. Tobinick | Cytokine antagonists for the treatment of localized disorders |
| US6982089B2 (en) | 1999-02-24 | 2006-01-03 | Tact Ip, Llc | Cytokine antagonists for neurological and neuropsychiatric disorders |
| US6419934B1 (en) | 1999-02-24 | 2002-07-16 | Edward L. Tobinick | TNF modulators for treating neurological disorders associated with viral infection |
| US6177077B1 (en) | 1999-02-24 | 2001-01-23 | Edward L. Tobinick | TNT inhibitors for the treatment of neurological disorders |
| US6015557A (en) | 1999-02-24 | 2000-01-18 | Tobinick; Edward L. | Tumor necrosis factor antagonists for the treatment of neurological disorders |
| US6537549B2 (en) | 1999-02-24 | 2003-03-25 | Edward L. Tobinick | Cytokine antagonists for the treatment of localized disorders |
| US6507788B1 (en) * | 1999-02-25 | 2003-01-14 | Société de Conseils de Recherches et D'Applications Scientifiques (S.C.R.A.S.) | Rational selection of putative peptides from identified nucleotide, or peptide sequences, of unknown function |
| US6537785B1 (en) | 1999-09-14 | 2003-03-25 | Genzyme Glycobiology Research Institute, Inc. | Methods of treating lysosomal storage diseases |
| WO2001059459A2 (en) | 2000-02-08 | 2001-08-16 | University Of British Columbia | Compositions and methods for screening therapeutic agents |
| US6261595B1 (en) | 2000-02-29 | 2001-07-17 | Zars, Inc. | Transdermal drug patch with attached pocket for controlled heating device |
| WO2002013873A2 (en) * | 2000-08-17 | 2002-02-21 | Synapse Technologies, Inc. | P97-active agent conjugates and their methods of use |
| US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| BR0207283A (pt) | 2001-02-19 | 2004-08-17 | Merck Patent Gmbh | Anticorpos anti-egfr modificados com imunogenicidade reduzida |
| KR100945108B1 (ko) | 2001-06-13 | 2010-03-02 | 젠맵 에이/에스 | 표피 성장 인자 수용체 (ｅｇｆｒ)에 대한 인간모노클로날 항체 |
| US7595378B2 (en) | 2001-06-13 | 2009-09-29 | Genmab A/S | Human monoclonal antibodies to epidermal growth factor receptor (EGFR) |
| JP4202250B2 (ja) * | 2001-07-25 | 2008-12-24 | バイオマリン ファーマシューティカル インコーポレイテッド | 血液脳関門輸送を調節するための組成物および方法 |
| ES2561985T3 (es) | 2001-10-10 | 2016-03-01 | Ratiopharm Gmbh | Remodelación y glicoconjugación de anticuerpos |
| US7179617B2 (en) | 2001-10-10 | 2007-02-20 | Neose Technologies, Inc. | Factor IX: remolding and glycoconjugation of Factor IX |
| US20030072761A1 (en) | 2001-10-16 | 2003-04-17 | Lebowitz Jonathan | Methods and compositions for targeting proteins across the blood brain barrier |
| AU2003222568B2 (en) | 2002-01-11 | 2009-05-07 | Bioasis Technologies, Inc. | Use of P97 as an enzyme delivery system for the delivery of therapeutic lysosomal enzymes |
| US7244592B2 (en) | 2002-03-07 | 2007-07-17 | Dyax Corp. | Ligand screening and discovery |
| US20050026823A1 (en) | 2003-06-20 | 2005-02-03 | Biomarin Pharmaceutical Inc. | Use of the chaperone receptor-associated protein (RAP) for the delivery of therapeutic compounds to the brain and other tissues |
| DE10355904A1 (de) | 2003-11-29 | 2005-06-30 | Merck Patent Gmbh | Feste Formen von anti-EGFR-Antikörpern |
| AU2005211775B2 (en) | 2004-02-06 | 2009-10-08 | Biomarin Pharmaceutical Inc. | Manufacture of highly phosphorylated lysosomal enzymes and uses thereof |
| US7462697B2 (en) | 2004-11-08 | 2008-12-09 | Epitomics, Inc. | Methods for antibody engineering |
| US8236306B2 (en) | 2004-12-18 | 2012-08-07 | Edward Lewis Tobinick | Methods to facilitate transmission of large molecules across the blood-brain, blood-eye, and blood-nerve barriers |
| US7842467B1 (en) | 2005-05-12 | 2010-11-30 | Celera Corporation | Breast disease targets and uses thereof |
| US7723484B2 (en) | 2005-11-12 | 2010-05-25 | Applied Molecular Evolution, Inc. | Anti-EGFR antibodies |
| EA016609B1 (ru) | 2005-11-28 | 2012-06-29 | Генмаб А/С | Рекомбинантные моновалентные антитела и способы их получения |
| US7498142B2 (en) | 2006-01-31 | 2009-03-03 | Yeda Research And Development Co., Ltd. | Methods of identifying combinations of antibodies with an improved anti-tumor activity and compositions and methods using the antibodies |
| US8759297B2 (en) | 2006-08-18 | 2014-06-24 | Armagen Technologies, Inc. | Genetically encoded multifunctional compositions bidirectionally transported between peripheral blood and the cns |
| PL2308514T3 (pl) * | 2007-03-23 | 2013-11-29 | To Bbb Holding B V | Koniugaty do ukierunkowanego dostarczania leku poprzez barierę krew-mózg |
| US9365634B2 (en) | 2007-05-29 | 2016-06-14 | Angiochem Inc. | Aprotinin-like polypeptides for delivering agents conjugated thereto to tissues |
| KR20160125535A (ko) | 2008-03-18 | 2016-10-31 | 제넨테크, 인크. | 항-ｈｅｒ２ 항체-약물 접합체와 화학요법제의 병용물, 및 사용 방법 |
| KR20130103662A (ko) * | 2010-04-19 | 2013-09-24 | 엔라이프 떼라퓨틱스, 에스.엘. | 올리고뉴클레오티드 분자들의 특정 뉴런 유형들로의 선택적인 전달을 위한 조성물들 및 방법 |
| FR2959229B1 (fr) | 2010-04-21 | 2013-01-18 | Vect Horus | Derives peptidiques, leur preparation et leurs utilisations |
| SMT201900594T1 (it) | 2010-06-25 | 2019-11-13 | Shire Human Genetic Therapies | Metodi e composizioni per il rilascio nell’snc di iduronato-2-solfatasi |
| WO2011163648A1 (en) | 2010-06-25 | 2011-12-29 | Shire Human Genetic Therapies, Inc. | Cns delivery of therapeutic agents |
| US20130236442A1 (en) | 2010-11-12 | 2013-09-12 | Green Cross Corporation | Iduronate-2-sulfatase and use thereof |
| BR112014002219A2 (pt) | 2011-07-05 | 2018-08-07 | Bioasis Technologies Inc | conjugados anticorpo p97 e métodos de sua utilização |
| ES2654111T3 (es) * | 2011-08-05 | 2018-02-12 | Bioasis Technologies Inc. | Fragmentos p97 con actividad de transferencia |
| WO2014022515A1 (en) | 2012-07-31 | 2014-02-06 | Bioasis Technologies, Inc. | Dephosphorylated lysosomal storage disease proteins and methods of use thereof |
| JP2016503394A (ja) * | 2012-10-26 | 2016-02-04 | エヌライフ、セラピューティックス、ソシエダッド、リミターダＮｌｉｆｅ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｓ．Ｌ． | 細胞型へのオリゴヌクレオチド分子の選択的送達のための組成物および方法 |
| ES2774549T3 (es) * | 2013-03-13 | 2020-07-21 | Bioasis Technologies Inc | Fragmentos de P97 y usos de los mismos |
| US20150093399A1 (en) | 2013-08-28 | 2015-04-02 | Bioasis Technologies, Inc. | Cns-targeted conjugates having modified fc regions and methods of use thereof |
| WO2015117121A1 (en) | 2014-02-03 | 2015-08-06 | Bioasis Technologies, Inc. | P97 fusion proteins |
| JP6605482B2 (ja) | 2014-02-19 | 2019-11-13 | バイオアシス テクノロジーズ インコーポレイテッド | Ｐ９７−ｉｄｓ融合タンパク質 |
-
2015
- 2015-05-01 CA CA2943890A patent/CA2943890A1/en active Pending
- 2015-05-01 EP EP15721106.1A patent/EP3137610B1/en not_active Not-in-force
- 2015-05-01 US US15/306,978 patent/US10058619B2/en active Active
- 2015-05-01 WO PCT/US2015/028743 patent/WO2015168521A2/en not_active Ceased
- 2015-05-01 JP JP2016564998A patent/JP6847664B2/ja not_active Expired - Fee Related
- 2015-05-01 CN CN201580022655.1A patent/CN106413757B/zh not_active Expired - Fee Related
- 2015-05-01 AU AU2015252906A patent/AU2015252906C1/en not_active Ceased